Roberto Ferrara, Medical Oncologist,Researcher in Thoracic Oncology and Molecular Immunology at Vita-Salute San Raffaele University, posted on LinkedIn:
“Time to tailor chemo-IO in early stage NSCLC. Reconstructed individual patient data analysis shows NEOAD= PERIOP in pCR, MPR and no-MPR. PERIOP performs well in pure-MPR (1-10% RVT). While pCR or no-MPR may deserve future descalation or escalation treatment strategies, respectively.”
Authors: Antonio Nuccio et al.
